StreetAlpha
13F holdings · Q2 2026

Casdin Capital

New York, NY · files as Casdin Capital, LLC
Holdings as of Jun 30, 2026Filed Aug 14, 2026Next filing due Nov 16, 2026CIK 1534261

Casdin Capital reported 43 stocks worth $2B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are RVMD (24.2%), RLAY (15.0%) and WGS (12.7%). Compared with Q1 2026, the fund opened new positions in PBLS, SION and SRPT, added to RLAY, WGS and DNLI, trimmed TXG and GH and sold out of QGEN, TEM and MLTX.

Reported value$2B+51.3% vs last quarter
Stocks held436 new · 3 sold out
Top 5 weight63.2%very concentrated
Turnover17%of the portfolio changed
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
RVMD
Revolution Medicines Inc
$483M24.2%2.6MNo change8 of 8
2
RLAY
Relay Therapeutics Inc
$300M15.0%16M+1.6M (+11%)8 of 8
3
WGS
Genedx Holdings Corp
$254M12.7%3.7M+700K (+23%)8 of 8
4
BIOLIFE SOLUTIONS INC
$131M6.6%4.7M−1.3M (−22%)8 of 8
5
ILMN
Illumina Inc
$93.2M4.7%530KNo change8 of 8
6
LAB
Standard Biotools Inc
$73M3.7%88.8MNo change8 of 8
7
GPCR
Structure Therapeutics Inc
$63.1M3.2%1.2MNo change8 of 8
8
DNLI
Denali Therapeutics Inc
$52.6M2.6%2M+205K (+11%)8 of 8
9
NGNE
Neurogene Inc
$48.6M2.4%1.5M+125K (+9%)8 of 8
10
BEAM
Beam Therapeutics Inc
$46.3M2.3%1.4MNo change8 of 8
🔒 33 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q1 2026, gone in Q2 2026
StockValue last quarterShares sold
QGEN
Qiagen NV Ord Shares
$14.4M360K
TEM
Tempus AI Inc
$13.3M294K
MLTX
Moonlake Immunotherapeutics
$8.4M450K

Reported value

last 8 quarters
$1.5BQ3 '24
$1.5BQ4 '24
$1.2BQ1 '25
$1.1BQ2 '25
$1.2BQ3 '25
$1.6BQ4 '25
$1.3BQ1 '26
$2BQ2 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q2 2026

straight from the SEC
FiledFormQuarter
Aug 14, 202613F-HRQ2 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Casdin Capital 13F FAQ

What does Casdin Capital own?

Casdin Capital reported 43 stocks worth $2B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are RVMD (24.2%), RLAY (15.0%) and WGS (12.7%). The table above lists every position in the filing (the top 10 without an account).

What did Casdin Capital buy and sell in Q2 2026?

Compared with Q1 2026: 6 new positions, 9 added to, 3 trimmed and 3 sold out. New positions include PBLS, SION and SRPT. It sold all of QGEN, TEM and MLTX.

When will Casdin Capital file its next 13F?

Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.

How much is Casdin Capital's portfolio worth?

The Q2 2026 filing reports $2B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.